1. Home
  2. IGC vs AAME Comparison

IGC vs AAME Comparison

Compare IGC & AAME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IGC
  • AAME
  • Stock Information
  • Founded
  • IGC 2005
  • AAME 1968
  • Country
  • IGC United States
  • AAME United States
  • Employees
  • IGC N/A
  • AAME N/A
  • Industry
  • IGC Biotechnology: Pharmaceutical Preparations
  • AAME Life Insurance
  • Sector
  • IGC Health Care
  • AAME Finance
  • Exchange
  • IGC Nasdaq
  • AAME Nasdaq
  • Market Cap
  • IGC 23.8M
  • AAME 31.4M
  • IPO Year
  • IGC N/A
  • AAME N/A
  • Fundamental
  • Price
  • IGC $0.40
  • AAME $1.63
  • Analyst Decision
  • IGC Strong Buy
  • AAME
  • Analyst Count
  • IGC 2
  • AAME 0
  • Target Price
  • IGC $3.63
  • AAME N/A
  • AVG Volume (30 Days)
  • IGC 720.2K
  • AAME 7.2K
  • Earning Date
  • IGC 11-11-2024
  • AAME 11-11-2024
  • Dividend Yield
  • IGC N/A
  • AAME 2.45%
  • EPS Growth
  • IGC N/A
  • AAME N/A
  • EPS
  • IGC N/A
  • AAME N/A
  • Revenue
  • IGC $1,062,000.00
  • AAME $186,001,000.00
  • Revenue This Year
  • IGC N/A
  • AAME N/A
  • Revenue Next Year
  • IGC $13.57
  • AAME N/A
  • P/E Ratio
  • IGC N/A
  • AAME N/A
  • Revenue Growth
  • IGC N/A
  • AAME N/A
  • 52 Week Low
  • IGC $0.25
  • AAME $1.43
  • 52 Week High
  • IGC $0.91
  • AAME $3.00
  • Technical
  • Relative Strength Index (RSI)
  • IGC 58.99
  • AAME 49.71
  • Support Level
  • IGC $0.35
  • AAME $1.51
  • Resistance Level
  • IGC $0.41
  • AAME $1.73
  • Average True Range (ATR)
  • IGC 0.03
  • AAME 0.07
  • MACD
  • IGC 0.00
  • AAME -0.01
  • Stochastic Oscillator
  • IGC 33.83
  • AAME 42.86

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

About AAME Atlantic American Corporation

Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts. It also provides tailored business automobile insurance coverage, on a multi-year contract basis, to state governments and local municipalities, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance. It earns revenue from the collection of premiums and investment income.

Share on Social Networks: